Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Robert Dean, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Amanda L. Maggiotto, BS, CCRP, Jennifer Bates, BS, CCRP, Stephen D. Smith, MD, Brian J. Bolwell, MD, John Sweetenham, MD

Blood (2011) 118 (21): 1621.

https://doi.org/10.1182/blood.V118.21.1621.1621

Published: 2011

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Journal Articles

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Stephen S. Smith, MD, Brian Bolwell, MD, Anjali Advani, MD, Steven Andresen, DO, Josephine Chan, Robert Dean, MD, Eric Hsi, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Ronald Sobecks, MD, John Sweetenham, MD

Blood (2008) 112 (11): 1137.

https://doi.org/10.1182/blood.V112.11.1137.1137

Published: 2008

Journal Articles

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Christy Stotler, DO, Paul Elson, ScD, Brian Bolwell, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Robert Dean, MD, Steven Andresen, DO, Edward Copelan, MD, Josephine Chan, John Sweetenham, MD

Blood (2008) 112 (11): 3279.

https://doi.org/10.1182/blood.V112.11.3279.3279

Published: 2008

Journal Articles

Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant.

Christy Stotler, DO, Lisa Rybicki, Matt Kalaycio, MD, Robert Dean, Edward A. Copelan, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Steven Andresen, DO, John Sweetenham, MD, Kelly Cherni, RN, Josephine Chan, Brian J. Bolwell, MD

Blood (2008) 112 (11): 2155.

https://doi.org/10.1182/blood.V112.11.2155.2155

Published: 2008

Journal Articles

MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

Eric D Hsi, MD, Lisa Rimsza, MD, Bryan H Goldman, MS, James R. Cook, MD, PhD, Raymond R. Tubbs, DO, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Richard I Fisher, MD, John Sweetenham, MD

Blood (2008) 112 (11): 376.

https://doi.org/10.1182/blood.V112.11.376.376

Published: 2008

Journal Articles

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

Georg Lenz, MD, George Wright, PhD, Sandeep Dave, MD, Alexander Kohlmann, PhD, Wenming Xiao, PhD, John Powell, MS, Hong Zhao, Weihong Xu, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Lorraine May, MD, Dennis D. Weisenburger, MD, Tim Greiner, MD, Julie Vose, MD, James O. Armitage, MD, Javeed Iqbal, MD, Martin Bast, MD, Kai Fu, MD, Elias Campo, MD, Emili Montserrat, MD, Armando Lopez-Guillermo, MD, Pedro Jares, MD, Antonio Martinez, MD, Betty Gibbs, MD, Lisa M. Rimsza, MD, Richard I. Fisher, MD, Rita M. Braziel, MD, Ray Tubbs, MD, James Cook, MD, Brad Pohlman, MD, John Sweetenham, MD, Gunhild Troen, MD, Erlend B. Smeland, MD, Jan Delabie, MD, Stein Kvaloy, MD, Harald Holte, MD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD, Nicole Grant, MD, Elena Hartmann, MD, Andreas Rosenwald, MD, German Ott, MD, Hans-Konrad Muller-Hermelink, MD, T. Andrew Lister, MD, Mickey Williams, PhD, Lothar Wieczorek, PhD, Wing C. Chan, MD, Louis M. Staudt, MD, PhD

Blood (2007) 110 (11): 348.

https://doi.org/10.1182/blood.V110.11.348.348

Published: 2007

Journal Articles

Analysis of Factors Influencing Skin Toxicity after Autologous Hematopoeitic Stem Cell Transplant.

Anuj Mahindra, MD, Brian Bolwell, MD, Ronald Sobecks, MD, Lisa Rybicki, MS, Stacey Brown, Brad Pohlman, MD, Matt Kalaycio, MD, Robert Dean, MD, Steve Andresen, DO, John Sweetenham, MD, Edward Copelan, MD

Blood (2007) 110 (11): 2882.

https://doi.org/10.1182/blood.V110.11.2882.2882

Published: 2007

Journal Articles

Prognostic Impact of Elevated Pretransplant Serum Ferritin in Allogeneic Hematopoietic Stem Cell Transplantation.

Anuj Mahindra, MD, Brian Bolwell, MD, Ronald Sobecks, MD, Lisa Rybicki, MS, Stacey Brown, Brad Pohlman, MD, Robert Dean, MD, Steve Andresen, DO, Matt Kalaycio, MD, John Sweetenham, MD, Edward Copelan, MD

Blood (2007) 110 (11): 1109.

https://doi.org/10.1182/blood.V110.11.1109.1109

Published: 2007

Journal Articles

Elevated Ferritin Is Associated with Poorer Survival Following Nonablative Allogeneic Transplantation.

Anuj Mahindra, MD, Ronald Sobecks, MD, Lisa Rybicki, MS, Stacey Brown, Brad Pohlman, MD, Matt Kalaycio, MD, Robert Dean, MD, Steve Andresen, DO, John Sweetenham, MD, Brian Bolwell, MD, Edward Copelan, MD

Blood (2007) 110 (11): 1986.

https://doi.org/10.1182/blood.V110.11.1986.1986

Published: 2007

Journal Articles

Long Term Follow Up with Etoposide Priming in Patients with Lymphoma.

Anuj Mahindra, MD, Brian Bolwell, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Stacey Brown, Robert Dean, MD, Matt Kalaycio, MD, Steve Andresen, DO, Ronald Sobecks, MD, John Sweetenham, MD, Edward Copelan, MD

Blood (2007) 110 (11): 1895.

https://doi.org/10.1182/blood.V110.11.1895.1895

Published: 2007

Journal Articles

Elevated Pretransplant Serum Ferritin in Autologous Stem Cell Transplant.

Blood (2007) 110 (11): 606.

https://doi.org/10.1182/blood.V110.11.606.606

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant.

MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.

Analysis of Factors Influencing Skin Toxicity after Autologous Hematopoeitic Stem Cell Transplant.

Prognostic Impact of Elevated Pretransplant Serum Ferritin in Allogeneic Hematopoietic Stem Cell Transplantation.

Elevated Ferritin Is Associated with Poorer Survival Following Nonablative Allogeneic Transplantation.

Long Term Follow Up with Etoposide Priming in Patients with Lymphoma.

Elevated Pretransplant Serum Ferritin in Autologous Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only